A New Way to Treat Your Thyroid Eye Disease (TED)
Patient portrayal
Patient portrayal
Patient portrayal
Including eye bulging and double vision
Self-administer at home after training and approval by your doctor
Supported by over 7 years of clinical experience with consistent safety
*ENSPRYNG is designed to target the action of interleukin 6 (IL-6), a protein that may play an important role in TED. The exact way ENSPRYNG works is not fully known.
ENSPRYNG is a prescription medicine used to treat thyroid eye disease (TED) no matter how severe it is or how long a person has had it.
ENSPRYNG is the first and only FDA-approved treatment for TED which is designed to target the action of interleukin-6 (IL-6), a protein that may play an important role in TED. The exact way ENSPRYNG works is not fully known.
ENSPRYNG can be self-administered at home following training and approval with your doctor. Your doctor will check if you have an infection and treat it if needed before you start or while taking ENSPRYNG. Your doctor should test you for hepatitis and tuberculosis (TB) before you start taking ENSPRYNG, and all required vaccinations should be completed before starting ENSPRYNG. View What to know before starting ENSPRYNG.
ENSPRYNG has a well-established safety profile, supported by over 7 years of clinical experience with consistent safety. ENSPRYNG may cause serious side effects including infections, increased liver enzymes, low neutrophil count, and serious allergic reactions. These are not all the possible side effects of ENSPRYNG. Review ENSPRYNG Important Safety Information.
FDA=Food and Drug Administration; IL-6=interleukin 6; TED=thyroid eye disease.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.